Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy

Cardiol Young. 2014 Aug;24(4):764-6. doi: 10.1017/S104795111300125X. Epub 2013 Sep 13.

Abstract

A 7-year-old male patient who had abdominal swelling and eyelid oedema was diagnosed with restrictive cardiomyopathy. His serum albumin level was 2.3 g/dl. Protein-losing enteropathy due to restrictive cardiomyopathy was diagnosed and oral budesonide was started. His serum albumin level began to rise and ascites and peripheric oedema disappeared. The patient underwent a successful cardiac transplantation and budesonide was stopped. After the heart transplantation, the albumin level decreased to 2.3 g/dl, and therefore it was restarted. When the serum albumin level increased, the budesonide dose was tapered and stopped in 1 month. Budesonide may be an effective drug in patients with protein-losing enteropathy due to heart failure.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Ascites / drug therapy*
  • Ascites / etiology
  • Budesonide / administration & dosage*
  • Cardiomyopathy, Restrictive / complications
  • Cardiomyopathy, Restrictive / surgery*
  • Child
  • Edema / drug therapy*
  • Edema / etiology
  • Glucocorticoids / administration & dosage*
  • Heart Transplantation*
  • Humans
  • Male
  • Protein-Losing Enteropathies / blood
  • Protein-Losing Enteropathies / drug therapy*
  • Protein-Losing Enteropathies / etiology
  • Serum Albumin
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Serum Albumin
  • Budesonide